Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
1(8%)
Results Posted
83%(5 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_1
2
17%
Ph phase_2
8
67%
Ph not_applicable
2
17%

Phase Distribution

2

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
8(66.7%)
N/ANon-phased studies
2(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(6)
Terminated(2)
Other(3)

Detailed Status

Completed6
unknown3
Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (16.7%)
Phase 28 (66.7%)
N/A2 (16.7%)

Trials by Status

recruiting18%
unknown325%
completed650%
terminated217%

Recent Activity

1 active trials
Showing 5 of 12
completedphase_2

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

NCT02684162
recruitingphase_2

A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

NCT05788679
terminatednot_applicable

AML Therapy With Irradiated Allogeneic Cells

NCT02105116
completednot_applicable

Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant

NCT00534118
completedphase_1

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

NCT00006251
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT02684162Phase 2

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

Completed
NCT05788679Phase 2

A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

Recruiting
NCT02105116Not Applicable

AML Therapy With Irradiated Allogeneic Cells

Terminated
NCT00534118Not Applicable

Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant

Completed
NCT00006251Phase 1

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Completed
NCT00923910Phase 1

Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

Completed
NCT01118013Phase 2

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Terminated
NCT00006252Phase 2

Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma

Completed
NCT00907036Phase 2

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

Unknown
NCT00908180Phase 2

Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Unknown
NCT00720447Phase 2

Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Unknown
NCT00031655Phase 2

Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission

Completed

All 12 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
12